No Data
No Data
Citi Maintains Apellis Pharmaceuticals(APLS.US) With Buy Rating, Maintains Target Price $60
Citi analyst Yigal Nochomovitz maintains $Apellis Pharmaceuticals(APLS.US)$ with a buy rating, and maintains the target price at $60.According to TipRanks data, the analyst has a success rate of 45.4%
Piper Sandler Maintains Apellis Pharmaceuticals(APLS.US) With Hold Rating, Maintains Target Price $46
Piper Sandler analyst Biren Amin maintains $Apellis Pharmaceuticals(APLS.US)$ with a hold rating, and maintains the target price at $46.According to TipRanks data, the analyst has a success rate of 42
Piper Sandler Reaffirms Their Hold Rating on Apellis Pharmaceuticals (APLS)
Analysts' Opinions Are Mixed on These Healthcare Stocks: Apellis Pharmaceuticals (APLS) and EDAP TMS (EDAP)
Buy Rating Affirmed on Apellis Pharmaceuticals Amid Promising Pegcetacoplan Trials and Expert Optimism
Jefferies Maintains Apellis Pharmaceuticals(APLS.US) With Buy Rating, Maintains Target Price $80
Jefferies analyst Akash Tewari maintains $Apellis Pharmaceuticals(APLS.US)$ with a buy rating, and maintains the target price at $80.According to TipRanks data, the analyst has a success rate of 59.5%
EZ_moneyOP : did you see those PTs![grin 😁](https://static.moomoo.com/nnq/emoji/static/image/img-apple-64/1f601.png)
EZ_moneyOP : back to +40